Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DXC005 (Hangzhou DAC Biotechnology)
- Development stage
- Preclinical
- Lead developer
- Hangzhou DAC Biotech
- Modality
- Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
01
Overview
DXC005 (Hangzhou DAC Biotechnology): sourced facts only. name: "DXC005 is a novel MUC1-targeting antibody-drug conjugate (ADC), generated by conjugating a Tubulysin B analogue to a recombinant humanized anti-Muc1 monoclonal antibody." [DOI:10.1158/1538-7445.am2024-1883]; target: "DXC005 is a novel MUC1-targeting antibody-drug conjugate (ADC), generated by conjugating a Tubulysin B analogue to a recombinant humanized anti-Muc1 monoclonal antibody." [DOI:10.1158/1538-7445.am2024-1883]; developer: "1Hangzhou DAC Biotechnology Co., Ltd., Hangzhou City, China." [DOI:10.1158/1538-7445.am2024-1883]; modality: "DXC005 is a novel MUC1-targeting antibody-drug conjugate (ADC), generated by conjugating a Tubulysin B analogue to a recombinant humanized anti-Muc1 monoclonal antibody." [DOI:10.1158/1538-7445.am2024-1883]; stage: "Preclinical studies have confirmed the efficacy of DXC005 monotherapy (2.5 mg/kg, 5 mg/kg, 10 mg/kg in one administration) in the HuPrime ® pancreatic cancer PDX model (PA1194)." [DOI:10.1158/1538-7445.am2024-1883]
02
Targets
MUC1 (Mucin-1 Antigen)
Beyond the preview
Go deeper on DXC005 (Hangzhou DAC Biotechnology).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DXC005 (Hangzhou DAC Biotechnology).